Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
Clinical trial NCT01207388 · COMPLETED
Trial details
- NCT number
- NCT01207388
- Sponsor
- Amgen Research (Munich) GmbH
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-11-01
- Primary completion
- 2014-02-01
- Enrollment
- 116
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.